Icon Cancer Centre to launch first-of-its-kind comprehensive private theranostics and imaging centre at Western Australia’s Hollywood Medical Centre

A partnership between Icon Cancer Centre and Perth Molecular Imaging and Theranostics Centre (PMITC) is set to advance cancer care in Western Australia, with the launch of a new comprehensive theranostics and molecular imaging centre located at the Hollywood Medical Centre adjacent to Hollywood Private Hospital. 

The first-of-its-kind in the state, the new Icon Cancer Centre will deliver an integrated private service combining advanced PET-CT and SPECT-CT imaging, targeted radiopharmaceutical therapies, including theranostics, and access to global clinical trials enhancing access to precision medicine for local, interstate, and international patients.

While theranostics services are available in Western Australia this marks the first dedicated centre with all imaging services under one roof centrally located.  

The centre will be located within the Hollywood Medical Centre on the campus of Ramsay Health Care’s flagship Hollywood Private Hospital, the largest private hospital in the country.

This convenient location helps meet the growing need for molecular imaging and therapy services, making it easier for more people across the state to receive the care they need.  

Equipped with Siemens Healthineers’ Biograph Trinion PET-CT, a first in WA, and Symbia Pro.specta X3 SPECT/CT, the facility offers highly advanced imaging technology that support diagnosis, staging and treatment of cancers including prostate cancer and neuroendocrine tumours, as well as new and developing uses in neurology and cardiology. 

Theranostics is a growing area of medicine that combines advanced diagnostic imaging with highly targeted treatment. It identifies a person’s unique cancer cells and delivers personalised targeted therapy to the cancer and aims to slow the growth and spread of cancer, relieve symptoms and maintain or improve quality of life. Theranostics may be considered for people with advanced cancer, when standard treatment options are unsuitable or no longer effective and symptoms are affecting quality of life. 

“Theranostics is changing the way we treat cancer. We’re giving patients more therapy options and seeing great results. It’s highly personal targeted treatment resulting in fewer long-term side effects and better outcomes – so patients are living longer and able to spend more quality time with loved ones,” said Dr Lenzo.     

By 2035, it’s expected that up to 60% of radiation therapy treatments will use these special medicines called radiopharmaceuticals. The new centre follows Icon’s successful launch of its first theranostics service at Icon Cancer Centre North Lakes in Brisbane and continues to build out cancer care in WA complementing Icon Cancer Centre locations in Rockingham and Midland. It also reflects Icon’s commitment to investing in a full suite of precision medicine technologies including radiation therapy machines, Gamma Knife and CyberKnife.  

In addition to providing access to pharmaceutical-sponsored clinical trials, the centre will also serve as a training hub for clinicians across Asia, with plans to collaborate with Siemens Healthineers and international partners.   

The new centre* is scheduled to open in the last quarter of this year and is positioned to become a leader in precision medicine innovation and care.  

*Subject to commercials and final approvals